trending Market Intelligence /marketintelligence/en/news-insights/trending/bfpwyjl0470yv6kkqmc6ka2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Intellipharmaceutics receives US, Canadian patents for overdose prevention tech

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Intellipharmaceutics receives US, Canadian patents for overdose prevention tech

Intellipharmaceutics International Inc. received patents from the U.S. Patent and Trademark Office and the Canadian Intellectual Property Office for its overdose prevention technology.

The patents cover aspects of Intellipharmaceutics International's Paradoxical OverDose Resistance Activating System delivery technology, designed to prevent overdose when more pills than prescribed are swallowed intact.

The company plans to incorporate its technology in an alternative product candidate for Rexista, its abuse-deterrent oxycodone hydrochloride extended release tablets that are pending approval from the U.S. FDA.